An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy

NCT02589717 | Unknown

• 1 other identifier: ML29725
• Study Type: expanded_access
• Target: N/A
• Locations: 1 country
• Sites: 40

Brief Summary

This is an open-label, multicenter, single-arm, expanded access program (EAP) designed to provide atezolizumab access to participants with locally advanced or metastatic urothelial carcinoma that has progressed on, or is intolerant to, a platinum-containing chemotherapy regimen.

Conditions

Urothelial Carcinoma

Interventions

Atezolizumab [TECENTRIQ] DRUG

Atezolizumab 1200 mg will be administered by IV infusion q3w. Initial IV infusion will be given over 60 minutes and subsequent infusions will be given over 30 minutes.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Able to comply with the study protocol, in the investigator's judgment
• Histologically or cytologically documented locally advanced or metastatic urothelial carcinoma (including renal pelvis, ureters, urinary bladder, and urethra)
• Disease progression during or following treatment with at least one platinum-containing regimen (e.g., gemcitabine and cisplatin \[GC\], methotrexate, vinblastine, doxorubicin, and cisplatin \[MVAC\], carboplatin and gemcitabine \[CarboGem\], etc.) for inoperable locally advanced or metastatic urothelial carcinoma or disease recurrence
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
• Life expectancy \>/= 12 weeks
• Adequate hematologic and end-organ function, defined by laboratory results obtained within 14 days prior to the first study treatment
• For women who are not postmenopausal (\>/= 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use single or combined non-hormonal contraceptive methods that result in a failure rate of \<1% per year during the treatment period and for at least 90 days after the last dose of study drug

You may not qualify if:

• Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment
• Treatment with chemotherapy 14 days prior to enrollment; however, participants may be re-screened after the 14-day washout period
• Treatment with radiotherapy 7 days prior to enrollment; however, participants may be re-screened after the 14-day washout period
• Known primary central nervous system (CNS) malignancy or symptomatic CNS metastases
• Pregnant or lactating, or intending to become pregnant during the study
• Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within 3 months prior to randomization, unstable arrhythmias, or unstable angina
• Severe infections within 4 weeks prior to enrollment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
• Received therapeutic oral or intravenous (IV) antibiotics within 14 days prior to enrollment; however, participants may be re-screened after the 14-day washout period
• Major surgical procedure within 4 weeks prior to enrollment or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis
• History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
• Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
• Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of disease or a condition that contraindicates the use of the investigational drug or renders the participant at high risk for treatment complications
• Participants with active hepatitis B
• Active tuberculosis
• Administration of a live, attenuated vaccine within 4 weeks prior to enrollment or anticipation that such a live, attenuated vaccine will be required during the study

Sponsors & Collaborators

• Genentech, Inc.: lead

Study Sites (40)

Unknown Facility

Scottsdale, Arizona, 85258, United States

Location

Unknown Facility

Tucson, Arizona, 85710, United States

Location

Unknown Facility

Duarte, California, 91010, United States

Location

Unknown Facility

Oakland, California, 94611, United States

Location

Unknown Facility

Stanford, California, 94305, United States

Location

Unknown Facility

Denver, Colorado, 80218, United States

Location

Unknown Facility

New Haven, Connecticut, 06520, United States

Location

Unknown Facility

West Hartford, Connecticut, 06119, United States

Location

Unknown Facility

Miami Beach, Florida, 33140, United States

Location

Unknown Facility

Tampa, Florida, 33612, United States

Location

Unknown Facility

Harvey, Illinois, 60426, United States

Location

Unknown Facility

Springfield, Illinois, 62794-9677, United States

Location

Unknown Facility

Goshen, Indiana, 46526, United States

Location

Unknown Facility

Indianapolis, Indiana, 46237, United States

Location

Unknown Facility

Sioux City, Iowa, 51101, United States

Location

Unknown Facility

Louisville, Kentucky, 40202, United States

Location

Unknown Facility

New Orleans, Louisiana, 70112, United States

Location

Unknown Facility

Boston, Massachusetts, 02114, United States

Location

Unknown Facility

Boston, Massachusetts, 02115, United States

Location

Unknown Facility

Boston, Massachusetts, 02215, United States

Location

Unknown Facility

Ann Arbor, Michigan, 48106, United States

Location

Unknown Facility

Detroit, Michigan, 48202, United States

Location

Unknown Facility

Saint Cloud, Minnesota, 56303, United States

Location

Unknown Facility

Jackson, Mississippi, 39202, United States

Location

Unknown Facility

St Louis, Missouri, 63110, United States

Location

Unknown Facility

Albuquerque, New Mexico, 87131-0001, United States

Location

Unknown Facility

Abany, New York, 12208, United States

Location

Unknown Facility

New York, New York, 10016, United States

Location

Unknown Facility

Rochester, New York, 14642, United States

Location

Unknown Facility

Columbus, Ohio, 43210, United States

Location

Unknown Facility

Eugene, Oregon, 97401-8122, United States

Location

Unknown Facility

Easton, Pennsylvania, 18045, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, 19107, United States

Location

Unknown Facility

Pittsburgh, Pennsylvania, 15212, United States

Location

Unknown Facility

Charleston, South Carolina, 29425, United States

Location

Unknown Facility

Houston, Texas, 77030, United States

Location

Unknown Facility

San Antonio, Texas, 78229, United States

Location

Unknown Facility

Charlottesville, Virginia, 22908, United States

Location

Unknown Facility

Norfolk, Virginia, 23502, United States

Location

Unknown Facility

Spokane, Washington, 99208, United States

Location

MeSH Terms

Conditions

Carcinoma, Transitional Cell

Interventions

atezolizumab

Condition Hierarchy (Ancestors)

Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms

Study Officials

• Clinical Trials

  Genentech, Inc.

  STUDY DIRECTOR

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 16, 2015
• First Posted: October 28, 2015
• Study Start: November 1, 2015
• Primary Completion: August 1, 2016
• Study Completion: August 1, 2016
• Last Updated: November 2, 2016

Record last verified: 2016-11

Locations

US (40)